40-301 : Special Drug Use-Results Survey of ADLUMIZ

40-301 : Special Drug Use-Results Survey of ADLUMIZ (Cancer cachexia: non-small cell lung cancer, gastric cancer, pancreatic cancer, large intestine cancer)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2011210014

Enrollment

5000

Registered

2021-05-25

Start date

2021-04-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer cachexia: non-small cell lung cancer, gastric cancer, pancreatic cancer, large intestine canc

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with (Cancer cachexia: non-small cell lung cancer, gastric cancer, pancreatic cancer, large intestine cancer) for whom ADLUMIZ is administered

Exclusion criteria

Exclusion criteria: patients who have not received ADLUMIZ

Design outcomes

Primary

Measure	Time frame
[Safety]Occurrence status of adverse drug reactions and infections, Occurrence status of adverse drug reactions corresponding to specified safety concerns, Factors that are considered to affect safety Specified safety concerns: hyperglycemia, hepatic impairment, conduction disorders, and interactions with moderate CYP3A4 inhibitors [Efficacy]Body weight increasing effect and appetite increasing effect	—

Measure

Time frame

[Safety]Occurrence status of adverse drug reactions and infections, Occurrence status of adverse drug reactions corresponding to specified safety concerns, Factors that are considered to affect safety Specified safety concerns: hyperglycemia, hepatic impairment, conduction disorders, and interactions with moderate CYP3A4 inhibitors [Efficacy]Body weight increasing effect and appetite increasing effect

—

Contacts

Public ContactTakafumi Nakao

Ono Pharmaceutical Co.,LTD

pms_contact_ml@ono-pharma.com+81-662225501

Outcome results